These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
410 related articles for article (PubMed ID: 27086494)
1. Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range Observations from the SPORTIF Trials. Proietti M; Lip GY Am J Med; 2016 Oct; 129(10):1110-6. PubMed ID: 27086494 [TBL] [Abstract][Full Text] [Related]
2. Prevention of stroke in patients with atrial fibrillation. Olsson SB; Halperin JL Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916 [TBL] [Abstract][Full Text] [Related]
3. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project. Fauchier L; Lecoq C; Clementy N; Bernard A; Angoulvant D; Ivanes F; Babuty D; Lip GY Chest; 2016 Apr; 149(4):960-8. PubMed ID: 26425935 [TBL] [Abstract][Full Text] [Related]
4. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. Akins PT; Feldman HA; Zoble RG; Newman D; Spitzer SG; Diener HC; Albers GW Stroke; 2007 Mar; 38(3):874-80. PubMed ID: 17255547 [TBL] [Abstract][Full Text] [Related]
5. Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. Proietti M; Lane DA; Lip GYH EBioMedicine; 2016 Jun; 8():309-316. PubMed ID: 27428440 [TBL] [Abstract][Full Text] [Related]
6. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Diener HC; Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807 [TBL] [Abstract][Full Text] [Related]
7. Effect of hypertension on anticoagulated patients with atrial fibrillation. Lip GY; Frison L; Grind M; Eur Heart J; 2007 Mar; 28(6):752-9. PubMed ID: 17289744 [TBL] [Abstract][Full Text] [Related]
10. Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores. Proietti M; Rivera-Caravaca JM; Esteve-Pastor MA; Marín F; Lip GYH Thromb Haemost; 2021 Aug; 121(8):1107-1114. PubMed ID: 33296920 [TBL] [Abstract][Full Text] [Related]
11. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?]. Selçuk H; Selçuk MT; Maden O Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079 [TBL] [Abstract][Full Text] [Related]
12. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? Go AS; Hylek EM; Chang Y; Phillips KA; Henault LE; Capra AM; Jensvold NG; Selby JV; Singer DE JAMA; 2003 Nov; 290(20):2685-92. PubMed ID: 14645310 [TBL] [Abstract][Full Text] [Related]
13. Relation of the SAMe-TT2R2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials. Proietti M; Lane DA; Lip GY Int J Cardiol; 2016 Aug; 216():168-72. PubMed ID: 27156060 [TBL] [Abstract][Full Text] [Related]
14. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Olsson SB; Lancet; 2003 Nov; 362(9397):1691-8. PubMed ID: 14643116 [TBL] [Abstract][Full Text] [Related]
15. [SPORTIF III and V trials: a major breakthrough for long-term oral anticoagulation]. Kulbertus H Rev Med Liege; 2003 Dec; 58(12):770-3. PubMed ID: 14978854 [TBL] [Abstract][Full Text] [Related]
16. [A comparison of CAS risk model and CHA Deng JL; He L; Jiang C; Lai YW; Long DY; Sang CH; Jia CQ; Feng L; Li X; Ning M; Hu R; Dong JZ; Du X; Tang RB; Ma CS Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Sep; 50(9):888-894. PubMed ID: 36096706 [No Abstract] [Full Text] [Related]
17. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Halperin JL; Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359 [TBL] [Abstract][Full Text] [Related]
18. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL; Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169 [TBL] [Abstract][Full Text] [Related]
19. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Westenbrink BD; Alings M; Granger CB; Alexander JH; Lopes RD; Hylek EM; Thomas L; Wojdyla DM; Hanna M; Keltai M; Steg PG; De Caterina R; Wallentin L; van Gilst WH Am Heart J; 2017 Mar; 185():140-149. PubMed ID: 28267467 [TBL] [Abstract][Full Text] [Related]